Competition for obesity drugs, clinical blind spots, and more news from ADA

With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race

It’s a sign of the times that this year’s American Diabetes Association (ADA) Scientific Sessions meeting in New Orleans featured more chatter on obesity drugs and pipeline programs than those spec | Eli Lilly emerged…